Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.34 |
| ▸ | BCL2L11 | O43521 | 2/20 | 0.34 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 7/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17542359 | 1.00 | KDM1A (0.44) | KDM1ASIGMAR1KDM4CMCL1BCL2L11 | |
| SCHEMBL17542361 | 1.00 | KDM1A (0.44) | KDM1ASIGMAR1KDM4CMCL1BCL2L11 | |
| SCHEMBL17565610 | 0.88 | KDM1A (0.43) | KDM1ASIGMAR1KDM4CMCL1BCL2L11 | |
| SCHEMBL23443007 | 0.83 | KDM1A (0.48) | KDM1ASIGMAR1KDM4CMCL1SRD5A1 | |
| SCHEMBL23442105 | 0.83 | KDM1A (0.39) | KDM1ASIGMAR1KDM4CMCL1BCL2L11 | |
| SCHEMBL26194443 | 0.80 | KDM1A (0.45) | KDM1ASIGMAR1KDM4CMAP3K14SRD5A1 | |
| SCHEMBL23480816 | 0.80 | KDM1A (0.38) | KDM1ASIGMAR1KDM4CMCL1MAP3K14 | |
| SCHEMBL26731741 | 0.78 | KDM1A (0.48) | KDM1ASIGMAR1SRD5A1SRD5A2 | |
| SCHEMBL23670805 | 0.76 | MAP3K14 (0.34) | MAP3K14 | |
| SCHEMBL23670802 | 0.76 | MAP3K14 (0.34) | MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197421-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12202842-B2 | MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230348494-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230212191-A1 | SPIRO-SULFONIMIDAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| US-11685747-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11667652-B2 | MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| EP-3601297-B9 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-3186259-B1 | TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-10100063-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180289720-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2018-10-11 | — | — | US | disclosed |
| WO-2018183418-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| WO-2017147410-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| EP-3186259-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN | Amgen Inc. (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20170088560-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9562061-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2016033486-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212191-A1 | SPIRO-SULFONIMIDAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | MCL1, BCL9, BCL2L1 | KDM1A 1494/4885SIGMAR1 2529/4885KDM4C 3808/4885 |
| US-20180289720-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | KDM1A 1229/4885SIGMAR1 4135/4885KDM4C 3542/4885 |
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL2L1, BCL9 | KDM1A 1335/4885SIGMAR1 4291/4885KDM4C 3574/4885 |
| US-12202842-B2 | MCL1 inhibitors | MCL1, BCL2L1, BCLAF1 | KDM1A 1499/4885SIGMAR1 3324/4885KDM4C 3679/4885 |
| US-11685747-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL2L1, BCL9 | KDM1A 1335/4885SIGMAR1 4291/4885KDM4C 3574/4885 |
| US-20230348494-A1 | MCL1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | KDM1A 1683/4885SIGMAR1 3384/4885KDM4C 3737/4885 |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL2L1, BCL9 | KDM1A 1335/4885SIGMAR1 4291/4885KDM4C 3574/4885 |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | KDM1A 1212/4885SIGMAR1 4041/4885KDM4C 3483/4885 |
| US-10100063-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | KDM1A 1212/4885SIGMAR1 4041/4885KDM4C 3483/4885 |
| US-20250197421-A1 | MCL1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | KDM1A 1683/4885SIGMAR1 3384/4885KDM4C 3737/4885 |
| US-20170088560-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | KDM1A 1212/4885SIGMAR1 4041/4885KDM4C 3483/4885 |
| US-11667652-B2 | MCL1 inhibitors | MCL1, BCL2L1, BCLAF1 | KDM1A 1683/4885SIGMAR1 3384/4885KDM4C 3737/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | KDM1A 1212/4885SIGMAR1 4041/4885KDM4C 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.